Insilico’s interim results story — a news article looking at a biotech AI company's recent financial jump and deal-driven momentum, useful for investors and industry watchers.
Key Takeaways
- Including collaborations with Lilly valued up to US$2.75 billion with a US$115 million upfront payment
- Insilico Medicine released interim results for the first half of 2026
- Company recorded a net profit of US$35.54 million